Irene Riera-Tur

Irene Riera-Tur

Auto-generated profile, based on publicly available information

Irene Riera-Tur

Secarna Pharmaceuticals GmbH & Co. KG, Planegg, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
VTVictoria A. Trinkaus
Victoria A. Trinkaus
IRIrene Riera-Tur
Irene Riera-Tur
AMAntonio Martínez-Sánchez
Antonio Martínez-Sánchez
FBFelix J. B. Bäuerlein
Felix J. B. Bäuerlein
QGQiang Guo
Qiang Guo
RFRubén Fernández-Busnadiego
Rubén Fernández-Busnadiego
The molecular architecture of α-Synuclein (α-Syn) inclusions, pathognomonic of various neurodegenerative disorders, remains unclear. α-Syn inclusions were long thought to consist mainly of α-Syn fibrils, but recent reports pointed to intracellular membranes as the major inclusion component. Here, we use cryo-electron tomography (cryo-ET) to image neuronal α-Syn inclusions in situ at molecular resolution. We show that inclusions seeded by α-Syn aggregates produced recombinantly or purified from patient brain consist of α-Syn fibrils crisscrossing a variety of cellular organelles. Using gold-labeled seeds, we find that aggregate seeding is predominantly mediated by small α-Syn fibrils, from which cytoplasmic fibrils grow unidirectionally. Detailed analysis of membrane interactions revealed that α-Syn fibrils do not contact membranes directly, and that α-Syn does not drive membrane clustering. Altogether, we conclusively demonstrate that neuronal α-Syn inclusions consist of α-Syn fibrils intermixed with membranous organelles, and illuminate the mechanism of aggregate seeding and cellular interaction.

11 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PCPatricia Yuste Checa
Patricia Yuste Checa
VTVictoria A. Trinkaus
Victoria A. Trinkaus
IRIrene Riera-Tur
Irene Riera-Tur
RIRahmi Imamoglu
Rahmi Imamoglu
TSTheresa F. Schaller
Theresa F. Schaller
FHF. Ulrich Hartl
F. Ulrich Hartl
Spreading of aggregate pathology across brain regions acts as a driver of disease progression in Tau-related neurodegeneration, including Alzheimer’s disease (AD) and frontotemporal dementia. Aggregate seeds released from affected cells are internalized by naïve cells and induce the prion-like templating of soluble Tau into neurotoxic aggregates. Here we show in a cellular model system and in neurons that Clusterin, an abundant extracellular chaperone, strongly enhances Tau aggregate seeding. Upon interaction with Tau aggregates, Clusterin stabilizes highly potent, soluble seed species. Tau/Clusterin complexes enter recipient cells via endocytosis and compromise the endolysosomal compartment, allowing transfer to the cytosol where they propagate aggregation of endogenous Tau. Thus, upregulation of Clusterin, as observed in AD patients, may enhance Tau seeding and possibly accelerate the spreading of Tau pathology.

21 December 2021 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
IRIrene Riera-Tur
Irene Riera-Tur
TSTillman Schäfer
Tillman Schäfer
DHDaniel Hornburg
Daniel Hornburg
AMArchana Mishra
Archana Mishra
MPMiguel da Silva Padilha
Miguel da Silva Padilha
IDIrina Dudanova
Irina Dudanova
The autophagy-lysosomal pathway is impaired in many neurodegenerative diseases characterized by protein aggregation, but the link between aggregation and lysosomal dysfunction remains poorly understood. Here, we combine cryo-electron tomography, proteomics, and cell biology studies to investigate the effects of protein aggregates in primary neurons. We use artificial amyloid-like β-sheet proteins (β proteins) to focus on the gain-of-function aspect of aggregation. These proteins form fibrillar aggregates and cause neurotoxicity. We show that late stages of autophagy are impaired by the aggregates, resulting in lysosomal alterations reminiscent of lysosomal storage disorders. Mechanistically, β proteins interact with and sequester AP-3 μ1, a subunit of the AP-3 adaptor complex involved in protein trafficking to lysosomal organelles. This leads to destabilization of the AP-3 complex, missorting of AP-3 cargo, and lysosomal defects. Restoring AP-3μ1 expression ameliorates neurotoxicity caused by β proteins. Altogether, our results highlight the link between protein aggregation, lysosomal impairments, and neurotoxicity.

1 October 2024 in Nucleic Acid Therapeutics
Verified
Journal Article
Open access
IRIrene Riera-Tur
Irene Riera-Tur
JHJulia Hinterdobler
Julia Hinterdobler
AMAndré Maaske
André Maaske
ASAnne Sadewasser
Anne Sadewasser
MSMonika Schell
Monika Schell
FJFrank Jaschinski
Frank Jaschinski
Early characterization of the immunostimulatory potential of therapeutic antisense oligonucleotides (ASOs) is crucial. At present, little is known about the toll-like receptor 9 (TLR9)-mediated immunostimulatory potential of third-generation locked nucleic acid (LNA)-modified ASOs. In this study, we have systematically investigated the TLR9-activating potential of LNA-modified oligonucleotides using different mouse and human cell culture systems. Although it has been reported that LNA modifications as well as cytosine methylation of 5'-cytosine-phosphate-guanine-3' (CpG) motifs can reduce TLR9 stimulation by phosphorothioate (PTO)-modified oligonucleotides, we identified CpG-containing LNA gapmers with substantial TLR9-stimulatory activity. We further identified immunostimulatory LNA gapmers without CpG motifs. Unexpectedly, methylation of cytosines only within the CpG motif did not necessarily reduce but could even increase TLR9 activation. In contrast, systematic methylation of all cytosines reduced or even abrogated TLR9 activation in most cases. Context dependently, the introduction of LNA-modifications into the flanks could either increase or decrease TLR9 stimulation. Overall, our results indicate that TLR9-dependent immunostimulatory potential is an individual feature of an oligonucleotide and needs to be investigated on a case-by-case basis.

16 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
PCPatricia Yuste Checa
Patricia Yuste Checa
VTVictoria A. Trinkaus
Victoria A. Trinkaus
IRIrene Riera-Tur
Irene Riera-Tur
RIRahmi Imamoglu
Rahmi Imamoglu
TSTheresa Schaller
Theresa Schaller
FHF. Ulrich Hartl
F. Ulrich Hartl
Spreading of aggregate pathology across brain regions acts as a driver of disease progression in Tau-related neurodegeneration, including Alzheimer’s disease (AD) and frontotemporal dementia. Aggregate seeds released from affected cells are internalized by naïve cells and induce the prion-like templating of soluble Tau into neurotoxic aggregates. Here we show in a cellular model system and in neurons that Clusterin, an abundant extracellular chaperone, strongly enhances Tau aggregate seeding. Upon interaction with Tau aggregates, Clusterin stabilizes highly potent, soluble seed species. Tau/Clusterin complexes enter recipient cells via endocytosis and compromise the endolysosomal compartment, allowing transfer to the cytosol where they propagate aggregation of endogenous Tau. Thus, upregulation of Clusterin, as observed in AD patients, may enhance Tau seeding and possibly accelerate the spreading of Tau pathology.